Browse the evidence

GLP-1 receptor agonists and dual receptor agonists effectively counteract hyperglycemia and obesity.

These medications may be prioritized in treatment plans for T2D patients with obesity.

Unimolecular GLP-1/GCG dual agonist and GLP-1/GIP/GCG triple agonist may offer superior weight loss efficacy over GLP-1 agonist.

Practitioners should consider these new agonists for potentially better weight loss outcomes.

Recent patents emphasize the development of GLP-1 receptor agonists (GLP-1RAs) for oral delivery and improved weight reduction effects.

Practitioners should consider the potential of new GLP-1RAs that are orally administered and may enhance weight loss.

GLP-1 receptor agonists demonstrated a mean systolic BP reduction of -3.37 mmHg and a mean diastolic BP reduction of -1.05 mmHg compared with placebo.

GLP-1 receptor agonists can be considered for managing blood pressure in overweight or obese patients.

The BP reduction effect of GLP-1 RAs was consistent across subgroups for diabetic status, formulation, follow-up duration, and route of administration.

GLP-1 receptor agonists can be effectively used across different patient subgroups for BP management.

Hormone delivery patterns were distinct between conditions but net exposure was similar.

Understanding distinct hormone delivery patterns can inform training strategies.

Tirzepatide is an efficacious and safe agent for the treatment of Type 2 Diabetes Mellitus (T2DM).

Practitioners can consider tirzepatide as a treatment option for managing T2DM.

Tirzepatide treatment significantly decreased serum glucose levels after fasting and improved glucose tolerance compared with semaglutide treatment.

Tirzepatide may offer better glycemic control than semaglutide in obese individuals.

Menstrual frequency increased in all groups from baseline to 12 months.

This suggests that while HIT did not specifically improve menstrual frequency, overall menstrual frequency improved over time.

More participants became pregnant in the low-volume HIT (LV-HIT) group compared to the control group.

This indicates that low-volume HIT may have a positive effect on fertility in women with PCOS.

Preoperative semaglutide use in patients with type II diabetes mellitus undergoing arthroscopic rotator cuff repair was associated with a lower incidence of any adverse events (11.0% vs 27.4%), severe adverse events (3.5% vs 10.5%), and minor adverse events (8.5% vs 22.0%) within 90 days post-surgery.

Practitioners may consider semaglutide as a beneficial preoperative intervention to reduce postoperative complications in diabetic patients.

Patients not using semaglutide had a greater odds ratio of experiencing any adverse events (3.65) and severe adverse events (3.62) compared to those using semaglutide.

Highlighting the importance of semaglutide in reducing the risk of complications may guide preoperative decisions.

Patients not using semaglutide had a higher 2-year rotator cuff retear rate (18.3% vs 12.5%) compared to those using semaglutide.

This finding suggests that semaglutide may improve long-term surgical outcomes in diabetic patients.

Ghrelin was elevated during fasting and suppressed by approximately 17% following a pre-exercise meal.

Endurance-trained athletes may experience significant changes in ghrelin levels based on fasting and meal timing.

Insulin and PYY were elevated approximately 157% and 40%, respectively, following the pre-exercise meal.

Practitioners should note the significant hormonal responses to pre-exercise meals in endurance athletes.

The interaction of ghrelin and PYY may be partially responsible for post-exercise appetite suppression.

Understanding the hormonal interactions can help in managing appetite in athletes post-exercise.

Gastric motor functions play a significant role in the development of satiation and satiety, impacting weight change.

Understanding gastric functions can help in designing effective weight loss interventions.

Pharmacological agents like liraglutide and dual agonists contribute to weight loss by retarding gastric emptying.

Incorporating GLP-1 agonists may enhance weight loss strategies.

Bariatric surgery and endoscopic gastroplasty alter gastric emptying and incretin responses in markedly divergent manners.

Choosing between surgical options may depend on their differing impacts on gastric function.

Semaglutide differs from other GLP-1 receptor agonists by having a longer half-life and producing greater weight loss.

Semaglutide may offer advantages over other GLP-1 agonists for weight loss due to its pharmacokinetic profile.

GLP-1 receptor agonists and co-agonists were associated with a lower risk of incident atrial fibrillation among individuals with overweight or obesity.

Practitioners may consider GLP-1RAs and co-agonists as potential options for reducing atrial fibrillation risk in overweight or obese patients.

Gynecologists play a pivotal role in the multidisciplinary approach to obesity management during menopause.

Gynecologists should integrate obesity management into routine care for menopausal women.

GLP-1 receptor agonists (GLP-1RAs) and combination therapy led to a significant decrease in mean glycated hemoglobin (HbA1c) levels by −3.5% at 12 months compared to DPP-4 inhibitors.

Practitioners can consider GLP-1RAs and combination therapy as effective options for managing HbA1c in liver transplant recipients with diabetes.

Dual-agonist and tri-agonist administration generally result in greater weight loss compared to GLP-1R agonists used alone.

Practitioners may consider dual- and tri-agonist therapies for enhanced weight loss in patients.